Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

Market Cap	3.69B -36.5%
Revenue (ttm)	892.24M +2.0%
Net Income	178.37M -44.1%
EPS	2.24 -44.4%
Shares Out	77.38M
PE Ratio	21.24
Forward PE	n/a
Dividend	2.00 (4.13%)
Ex-Dividend Date	Jun 1, 2026

Volume	273,828
Open	47.57
Previous Close	47.96
Day's Range	47.19 - 48.34
52-Week Range	39.80 - 76.80
Beta	0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About Hangzhou Alltest Biotech

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers COVID-19 solutions, such as antigen combo rapid and antigen test range; HUMAN RAPID TESTs, including women’s health, infectious disease, drugs of abuse, tumor markers, cardiac markers, home use, and other rapid tests; LF readers; and veterinary products comprising veterinary chemiluminescence and fluorescence immunoassay, veterinary LF readers, dry biochemistry, and immuno...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2009
• Employees: 992
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688606

Financial Performance

In 2025, Hangzhou Alltest Biotech's revenue was 905.34 million, an increase of 4.47% compared to the previous year's 866.58 million. Earnings were 220.19 million, a decrease of -27.20%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 24, 2026

Data Sources Report a data error